Sir Singh
10 Feb 2016
watch the spike up / new on its way Let's see if it's comes good. Just like 2010.
clockwurktangerine
02 Feb 2016
Hutch China Med is a properly structured pharma, backed by a country and institutional investors. Funding via institutions, PI's taking a structured punt.... Hutch China Med is a properly structured pharma, backed by a country and institutional investors. Funding via institutions, PI's taking a structured punt....
Warthog4
01 Feb 2016
Re: Good financing news Sounds good although market not impressed.Also, all we have to do now is sit and wait for a couple of years whilst the bureaucrats grind slowly into action
fredd1eboy
01 Feb 2016
Good financing news Sareum's clinical trial submissions trigger milestoneStockMarketWire | Mon, 1st February 2016 - 07:36Sareum said the Clinical Trial Applications for Phase I clinical trials of CCT245737 were submitted to the UK Medicines and Healthcare products Regulatory Agency (MHRA) on 29 January 2016. This triggers a GBP0.2m milestone payment from Cancer Research Technology Ltd.As reported previously, two clinical trials in cancer patients are planned, one with CCT245737 as a single anti-cancer agent and one in combination with standard-of-care chemotherapy.Once approval is obtained, these trials will be funded in collaboration with co-development partner, the CRT Pioneer Fund. In accordance with the CHK1 co-investment agreement, Sareum satisfied a financial commitment of £797,500 to the funding of this development phase in December 2015.
clockwurktangerine
21 Jan 2016
Hutch China Med Hutch China Med is a properly structured pharma, backed by a country and institutional investors. Funding via institutions, PI's taking a structured punt....
fredd1eboy
11 Jan 2016
Sareum.... Reneuron A couple of common denominators......cancer research and university college london. My hunch is watch this space as there are a few more common denominators. Freddie
fredd1eboy
07 Jan 2016
Re: Colour blind ? Same here. Pretty depressing!
Chancellor Jon
07 Jan 2016
Colour blind ? I looked at my portfolio just now and the only BLUE line is Sareum. All the others are RED.Go Sareum !
clockwurktangerine
06 Jan 2016
Need actuals... Potential yes, but for those who bought say 1.5p to 4p plus, massive actuals needed......a few thousand more pc.....GLA...
barno99
06 Jan 2016
Massive potential short and long term. A very interesting month ahead. When Phase 1 gets approval ( and it will ) the value of this Sareum will rocket. 1.21p has been mooted by the company as fair valuation already and we are only at .23p ( a joke) .There will be an scrabbling queue to give Sareum the feed capital to carry on th phase 2 and beyond. Great entry point and a multi bagger over the coming weeks for sure.. Our indicative sum of the parts valuation of 1.21 pence per share suggests significant upside with a clinical trial submission moving the company’s lead compound up the valuation chain. CHK1 inhibition is a mechanism of action being explored by several majors such as Merck, Roche’s Genentech and Lilly. Sareum believes that its candidate’s selectivity and oral pharmacokinetics compare favourably.
Warthog4
27 Oct 2015
Re: Results Usual "jam tomorrow" drivel,but if Uncle Tim can continue to raise cash each year to help finance his £100kpa lifestyle then he's not going to worry too much is he?As P T Barnum once said "there's one born every minute" and we, ladies and gents are the ones!!
fredd1eboy
26 Oct 2015
Results Final ResultsSareum Holdings plc (AIM: SAR), the specialist cancer drug discovery and development business, is pleased to announce its final results for the year ended 30 June 2015.Operational Highlights· Final preparations to submit CHK1 candidate for two concurrent Phase 1 clinical trials to assess different administration strategies: one as a single agent and the other in combination with chemotherapy.· CHK1 clinical trial applications expected to be submitted in Q1 2016 with trials to commence, subject to approval, shortly thereafter.· Preclinical development of Aurora+FLT3 inhibitor progressing to plan, with toxicology and additional efficacy studies ongoing.· TYK2 inhibitor lead molecule demonstrates striking decrease in psoriasis pathology in a disease model and encouraging results in a rheumatoid arthritis model.Financial Highlights· Net assets at period end were £1.86 million (2014: £1.72 million) of which £1.48 million comprised of cash at bank.· Loss on ordinary activities (after tax credit) of £1,255,368 (2014: Loss of £763,000), an improvement on expectations, reflecting re-phasing of commitments to CHK1 programme.· Successful placing in June 2015 to raise £1.44 million (before expenses) to satisfy ongoing commitments to CHK1 co-development payments and to provide additional working capital.Dr Tim Mitchell, Chief Executive Officer of the Company, said:"Good progress has been made in the last year, with two cancer programmes advancing through preclinical validation and potential new indications for our autoimmune disease programme. With the two planned in-human clinical trials for CHK1 commencing in early 2016, as well as the progress in our other programmes adding further commercial value, we look forward to next year with real anticipation and optimism."
nat81
10 Oct 2015
BROKER report forgot to ask, where can i find the latest broker target price for sar?
nat81
10 Oct 2015
Re: patent granted yet we are drifting back down
5 Iron
15 Sep 2015
patent granted Great news!
